- Home
- LRHC vs VBIO Comparison
LRHC vs VBIO Comparison
Compare LRHC & VBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LRHC | VBIO |
|---|---|---|
| Founded | 2004 | N/A |
| Country | United States | United States |
| Employees | N/A | 52 |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8M | 1.6M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LRHC | VBIO |
|---|---|---|
| Price | $0.86 | $0.28 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 69.5K | ★ 768.1K |
| Earning Date | 05-28-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $68,507,806.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.25 | $0.25 |
| 52 Week High | $9.72 | $0.61 |
Technical Indicators
Market Signals| Indicator | LRHC | VBIO |
|---|---|---|
| Relative Strength Index (RSI) | 39.87 | 32.74 |
| Support Level | $0.58 | $0.25 |
| Resistance Level | $1.20 | $0.43 |
| Average True Range (ATR) | 0.10 | 0.07 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 15.45 | 10.44 |
Price Performance
Historical ComparisonAbout LRHC La Rosa Holdings Corp.
La Rosa Holdings Corp operates in the U.S. residential real estate market. It is a holding company for agent-centric, technology-integrated, cloud-based, multi-service real estate companies. The company's business is organized based on the services it provides internally to the agents and to the public, which are residential and commercial real estate brokerage, franchising, real estate brokerage education and coaching, and property management. The company has six reportable segments, namely: Real Estate Brokerage Services (Residential), Franchising Services, Coaching Services, Property Management, Real Estate Brokerage Services (Commercial), and Title Settlement and Insurance. The company derives maximum revenue from the Real Estate Brokerage Services (Residential) segment.
About VBIO Valion Bio Inc. Common Stock
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.